However, because PD-L1 can be regarded as a tumor specific-antigen and an immune checkpoint molecule, αPD-L1 antibody may have a dual role in the BsTE construct: one as a tumor-T-cell engager and the other as an immune checkpoint blocker. This evidence concerns the gene CD274 and neoplasm.